Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant Intraperitoneal Gemcitabine for Resectable Pancreatic Adenocarcinoma
NCT01206296Phase 2Terminated
- Sponsor
- MedStar Health Research Institute
- Start
- Aug 2010
- Primary completion
- Feb 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of gemcitabine in pancreatic adenocarcinoma (PDAC), periampullary cancer, sponsored by MedStar Health Research Institute. Started Aug 2010; status: terminated.
02
Drugs
gemcitabine
03
Conditions
pancreatic adenocarcinoma (PDAC)periampullary cancer
Beyond the preview
Go deeper on NCT01206296.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01206296.